April 15, 2013 — Tomosynthesis (3-D mammography) is better able to show infiltrating ductal carcinoma than 2-D mammography in women at increased risk of breast cancer, a new clinical study shows.

As part of the study, six breast imaging specialists reviewed both 2-D and 3-D mammography images of 56 cancers diagnosed in patients at intermediate or high risk of breast cancer.

"We found that 41 percent (23/56 cancers) were better seen on tomosynthesis and 4 percent (2/56) were only seen on tomosynthesis," said Sarah O'Connell, a lead author of the study. Thirty percent of cancers (17/56) were better seen on 2-D mammography but none were only seen on 2-D mammography. The remaining were rated by the breast imaging specialists as being equally visible on both 2-D and 3- imaging, she said.

"The majority of cancers seen better or only on tomosynthesis were predominantly infiltrating ductal carcinoma, which typically presents as a mass, focal asymmetry or architectural distortion," said O'Connell.

The majority of cancers seen better or only on 2-D mammography were ductal carcinoma in situ (DCIS) which presents as calcifications, she said. "This was not surprising because tomosynthesis gives us the ability to scroll through the breast tissue in 1 mm sections, which provides us with more detail, but also may separate a cluster of calcifications, making them more difficult to identify," said O'Connell. O'Connell noted that work is being done to optimize visualization of calcifications on tomosynthesis.

The benefits of tomosynthesis are especially relevant to women at increased risk of breast cancer who have increased anxiety about breast screening and have the potential for biologically aggressive cancers, said O'Connell.

The study is part of the electronic exhibit program at the ARRS Annual Meeting in Washington, D.C.


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
Subscribe Now